Nanofibrous polycaprolactone-polyethylene glycol-based scaffolds embedded with pamidronate: fabrication and characterization

The present study outlines the fabrication and characterization of pamidronate (PDS) embedded nanofibrous scaffolds based on polycaprolactone/polycaprolactone-polyethyleneglycol-polycaprolactone (PCL/CEC) blends for osteoporotic bone defect management. The electrospinning technique has been utilized to fabricate PDS-loaded scaffolds and the effect of PDS on blends was evaluated by analyzing the surface morphology, wettability, biodegradability, and in vitro cytocompatibility. In vitro studies using human osteosarcoma cell lines (hOS) showed the non-cytotoxic nature of the scaffolds. The fibroporous architecture of PCL/CEC-PDS scaffolds along with their appropriate mechanical properties and ability to support cell growth in vitro suggests their potential for osteoporotic bone defect management.

Automated summary

This study outlines the fabrication and characterization of pamidronate (PDS) embedded nanofibrous scaffolds based on polycaprolactone/polycaprolactone-polyethyleneglycol-polycaprolactone (PCL/CEC) blends for osteoporotic bone defect management. The electrospinning technique was utilized to fabricate PDS-loaded scaffolds, and the effect of PDS on the blends was evaluated in terms of surface morphology, wettability, biodegradability, and in vitro cytocompatibility. The results showed that the PCL/CEC-PDS scaffolds had a fibroporous architecture, appropriate mechanical properties, and the ability to support cell growth, indicating their potential for managing osteoporotic bone defects.